openPR Logo
Press release

Shingles Vaccine Market -Trends, Outlook, and Opportunity Analysis, 2016-2024

02-10-2017 09:43 AM CET | Health & Medicine

Press release from: Shingles Vaccine Market

Shingles Vaccine Market -Trends, Outlook, and Opportunity

Shingles Vaccine Market Opportunity

Prevalence of shingles is increasing across the globe, fuelled mainly by increasing aging population. However, high cost of vaccines is limiting vaccination drive in emerging economies, characterized by inadequate insurance coverage. The major concern among healthcare experts is reduction in postherpetic neuralgia from the shingles vaccine. Zostavax has been successful to a certain extent in reducing postherpetic neuralgia due to the effect of the vaccine on reducing risk of developing herpes zoster. Better outcomes of Shingrix would be a boon for highly lucrative global shingles vaccines market.

Get Free PDF Research Brochure for more Professional and Technical Insights : https://www.coherentmarketinsights.com/insight/request-sample/73

The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had chicken pox in the past is at the risk of developing shingles. According to the Center for Disease Control and Prevention (CDC), there are an estimated one million cases of shingles reported every year in the U.S. Moreover, CDC states that around one in every three people in the U.S. will develop shingles in their lifetime. The risk of shingles increases with age, with most cases reported among people over 40 years old. This is mainly due to weakening of the immune system on account of increased stress and inadequate intake of essential nutrients to keep immunity strong.

Symptoms include skin rashes, nerve pain, vision loss, chills, upset stomach, muscle weakness, skin infection, and scarring. Treatment for shingles includes antiviral medication—acyclovir, valacyclovir, and famciclovir. These medicines help shorten the length and alleviate the severity of the illness. Further, analgesics may help relieve the pain.

Shingles Vaccine Market Dynamics

There is a safe and effective vaccines available for preventing shingles. The Zostavax vaccine licensed by Merck & Co., Inc. in 2006 is an effective vaccine against shingles. The vaccine is intended for use in population over 50 years of age. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The effectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for those 80 years of age and older. The vaccine was launched in the India market in February 2016, at half the price of the U.S. market. Zostavax, among the only shingles vaccine in the market, recorded sales of US$ 749 million in 2015.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/ongoing-insight/shingles-vaccines-market-73

In October 2016, GlaxoSmithKline (GSK)—a global leader in vaccines market—filed for U.S. FDA approval for its shingles vaccine, Shingrix. Shingrix has demonstrated better outcomes than Zostavax in its clinical trials. The vaccine was 90% efficacious in people over 70 years of age. The overall effectiveness of the vaccine is found to be 97%. Its higher effectiveness even among elder group of people is projected to increase its adoption across the globe. The impressive trail results would put Shingrix in a strong competitive position in the global market, currently monopolized by Zostavax. The company is reported to have filed for regulatory approvals in the Europe and Canada markets in 2016, followed by Japan in 2017. It is estimated that the sales of Shingrix would reach US$ 1 billion by 2021.

Shingles vaccines market is witnessing rapid influx of newer and expensive products. The industry is consolidated in nature however, new entrants are expected to emerge in the near future.

Shingles Vaccine Market Regional Analysis

North America and Europe are expected to collectively account for a major share of the market between 2016 and 2024. North America market growth is primarily driven by rising demand in the U.S., while the market in Europe is expected to be driven by increased therapeutic demand from European Union.

Asia Pacific shingles vaccine market is expected to witness highest growth over the forecast period. There is a wide addressable market that needs to be capitalized upon in the region especially in China and India. Active marketing and differential pricing would help companies to strengthen their market presence in Asia Pacific.

ABOUT US

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.

CONTACT US

Raj Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com/
Visit Blog : https://blog.coherentmarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Shingles Vaccine Market -Trends, Outlook, and Opportunity Analysis, 2016-2024 here

News-ID: 432209 • Views:

More Releases from Shingles Vaccine Market

SHINGLES VACCINE MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-2024
SHINGLES VACCINE MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTU …
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had
Shingles Vaccine Market, Company Analysis and Forecast to 2024
Shingles Vaccine Market, Company Analysis and Forecast to 2024
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had
Shingles Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024
Shingles Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportu …
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had

All 4 Releases


More Releases for Zostavax

Zostavax Industry Report 2025-2034: Market Dynamics, Drivers, And Forecasts
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Projected Growth of the Zostavax Market? In the latest years, the market size of Zostavax has amplified by XX (HCAGR). A rise from $XX million in 2024 to $XX million in 2025, showcasing a Compound Annual Growth Rate (CAGR) of XX% is projected. Several factors contributing to this growth
Shingrix (Zostavax) Market Forecast 2025-2034: Comprehensive Analysis And Growth …
"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Projected Growth of the Shingrix (Zostavax) Market? In the past few years, the Shingrix (Zostavax) market has seen a growth of XX (HCAGR). The market, which was worth $XX million in 2024, is projected to further grow to $XX million in 2025, implying a compound annual growth rate (CAGR)
In-Depth Analysis of the Shingrix Zostavax Market: Growth Opportunities, Key Tre …
What industry-specific factors are fueling the growth of the shingrix zostavax market? The Shingrix (Zostavax) market is also set to grow, driven by the increasing adoption of vaccination globally. Growing awareness of the effectiveness of vaccination in preventing diseases, combined with public health initiatives and improved healthcare infrastructure, is boosting vaccination rates. Shingrix, which protects against shingles, is particularly important for adults over 50, reducing the risk of shingles recurrence and
In-Depth Analysis of the Shingrix (Zostavax) Market: Growth Opportunities, Key T …
What Are the Projected Growth and Market Size Trends for the Shingrix (Zostavax) Market? The market size for shingrix (zostavax) has seen an increase of $XX (CAGR) in the latest years. The market is expected to surge from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. The growth seen in the previous period is due to factors such as enhanced vaccine
Impact Analysis of Covid-19 On Shingles Vaccine Market Rapidly Develop| Zostavax …
The Zostavax vaccine, licensed by Merck & Co., Inc. in 2006, is an effective vaccine against shingles. The vaccine is intended for the use in population age 50 years and above. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The effectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for those 80
Shingles Vaccines Market 2018 | Industry In-depth Analysis By Players GlaxoSmith …
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had